{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:33:35Z","timestamp":1778754815873,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007514","name":"Universit\u00e0 di Pisa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007514","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022412","name":"Dipartimento di Medicina Sperimentale e Clinica, Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002803","name":"Cariplo Foundation","doi-asserted-by":"publisher","award":["2014\\u20131962"],"award-info":[{"award-number":["2014\\u20131962"]}],"id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jpba.2026.117514","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T16:30:06Z","timestamp":1776011406000},"page":"117514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development and validation of an UHPLC-MS\/MS method for simultaneous quantification of Tazobactam, Meropenem, Vancomycin, Linezolid and Piperacillin in human plasma: Application in critically ill patients"],"prefix":"10.1016","volume":"277","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9503-8786","authenticated-orcid":false,"given":"Jacopo","family":"Lucchetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1976-699X","authenticated-orcid":false,"given":"Claudia","family":"Fracasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Cesana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6997-3893","authenticated-orcid":false,"given":"Francesca","family":"Dore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3525-3249","authenticated-orcid":false,"given":"Stefano","family":"Finazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1014-6225","authenticated-orcid":false,"given":"Marco","family":"Gobbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2026.117514_bib1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00134-019-05863-z","article-title":"Less empiric broad-spectrum antibiotics is more in the ICU","volume":"46","author":"da Fonseca Pestana Ribeiro","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jpba.2026.117514_bib2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jac\/dkh299","article-title":"Antibiotic usage in intensive care units: a pharmaco-epidemiological multicentre study","volume":"54","author":"Malacarne","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2026.117514_bib3","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jpba.2026.117514_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy313","article-title":"Sepsis in intensive care unit patients: worldwide data from the intensive care over nations audit","volume":"5","author":"Sakr","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.jpba.2026.117514_bib5","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jpba.2026.117514_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4046\/trd.2018.0041","article-title":"Sepsis: early recognition and optimized treatment","volume":"82","author":"Kim","year":"2019","journal-title":"Tuberc. Respir. Dis. (Seoul. )"},{"key":"10.1016\/j.jpba.2026.117514_bib7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jointm.2023.12.007","article-title":"Understanding antimicrobial pharmacokinetics in critically ill patients to optimize antimicrobial therapy: a narrative review","volume":"4","author":"Roger","year":"2024","journal-title":"J. Intensive Med."},{"key":"10.1016\/j.jpba.2026.117514_bib8","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/aas.12897","article-title":"Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study","volume":"61","author":"Bakke","year":"2017","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.jpba.2026.117514_bib9","doi-asserted-by":"crossref","DOI":"10.1186\/cc10441","article-title":"Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of \u03b2-lactams","volume":"15","author":"Gon\u00e7alves-Pereira","year":"2011","journal-title":"Crit. Care"},{"key":"10.1016\/j.jpba.2026.117514_bib10","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/CCM.0b013e318241e553","article-title":"Endotoxic shock alters the pharmacokinetics of lidocaine and monoethylglycinexylidide","volume":"40","author":"Roberts","year":"2012","journal-title":"Crit. Care Med"},{"key":"10.1016\/j.jpba.2026.117514_bib11","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/CCM.0b013e318241e553","article-title":"Effects of changes in arterial pressure on organ perfusion during septic shock","volume":"40","author":"Roberts","year":"2012","journal-title":"Crit. Care Med"},{"key":"10.1016\/j.jpba.2026.117514_bib12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000321488","article-title":"Principles of antibacterial dosing in continuous renal replacement therapy","volume":"30","author":"Choi","year":"2010","journal-title":"Blood Purif."},{"key":"10.1016\/j.jpba.2026.117514_bib13","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/CCM.0b013e318241e553","article-title":"Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy","volume":"40","author":"Roberts","year":"2012","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.jpba.2026.117514_bib14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13054-015-0818-8","article-title":"A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics","volume":"19","author":"Roberts","year":"2015","journal-title":"Crit. Care"},{"key":"10.1016\/j.jpba.2026.117514_bib15","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.clinthera.2016.07.169","article-title":"Pharmacokinetics and dosing of anti-infective drugs in patients on extracorporeal membrane oxygenation: a review of the current literature","volume":"38","author":"Sherwin","year":"2016","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jpba.2026.117514_bib16","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1097\/CCM.0b013e3181de0acf","article-title":"Common drug interactions leading to adverse drug events in the intensive care unit: management and pharmacokinetic considerations","volume":"38","author":"Papadopoulos","year":"2010","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.jpba.2026.117514_bib17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2165\/00003495-200161060-00005","article-title":"Management of antimicrobial use in the intensive care unit","volume":"61","author":"\u00c1lvarez-Lerma","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2026.117514_bib18","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jcrc.2013.03.003","article-title":"Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy","volume":"28","author":"Claus","year":"2013","journal-title":"J. Crit. Care"},{"key":"10.1016\/j.jpba.2026.117514_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00364","article-title":"Antimicrobial activity and resistance: influencing factors","volume":"8","author":"Li","year":"2017","journal-title":"Front. Pharm."},{"key":"10.1016\/j.jpba.2026.117514_bib20","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jpba.2026.117514_bib21","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"J.A. Roberts, Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jpba.2026.117514_bib22","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American society of health-system pharmacists, the infectious diseases society of America, the pediatr","volume":"77","author":"Rybak","year":"2020","journal-title":"Am. J. Heal. Pharm."},{"key":"10.1016\/j.jpba.2026.117514_bib23","doi-asserted-by":"crossref","DOI":"10.1515\/cclm-2016-0700","article-title":"The use of liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring of antibiotics in cancer patients","volume":"55","author":"El-Najjar","year":"2017","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.jpba.2026.117514_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jpba.2019.02.037","article-title":"LC-MS\/MS method for simultaneous determination of linezolid, meropenem, piperacillin and teicoplanin in human plasma samples","volume":"169","author":"Ferrari","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117514_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113273","article-title":"A liquid chromatography-tandem mass spectrometry platform for the routine therapeutic drug monitoring of 14 antibiotics: application to critically ill pediatric patients","volume":"186","author":"Barco","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117514_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116119","article-title":"Development of a rapid LC-MS\/MS method for simultaneous quantification of ten commonly used antibiotic drugs in human serum","volume":"244","author":"Ramirez","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117514_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114790","article-title":"Analytical validation of a novel UHPLC-MS\/MS method for 19 antibiotics quantification in plasma: implementation in a LC-MS\/MS Kit","volume":"163","author":"Mula","year":"2023","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.jpba.2026.117514_bib28","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/FTD.0000000000001017","article-title":"An ultra-high-performance liquid chromatography\u2013tandem mass spectrometry method for simultaneous determination of 4 \u03b2-lactam antibiotics, tazobactam, and linezolid in human plasma samples","volume":"44","author":"Piestansky","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2026.117514_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1044234","article-title":"An LC-MS\/MS method for the simultaneous determination of 18 antibacterial drugs in human plasma and its application in therapeutic drug monitoring","volume":"13","author":"Lu","year":"2022","journal-title":"Front. Pharm."},{"key":"10.1016\/j.jpba.2026.117514_bib30","article-title":"LC\u2013MS\/MS-based multiplex antibacterial platform for therapeutic drug monitoring in intensive care unit patients","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Pharm."},{"key":"10.1016\/j.jpba.2026.117514_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7048605","article-title":"UPLC-MS\/MS method for simultaneous determination of 14 antimicrobials in human plasma and cerebrospinal fluid: application to therapeutic drug monitoring","volume":"2022","author":"Sun","year":"2022","journal-title":"J. Anal. Methods Chem."},{"key":"10.1016\/j.jpba.2026.117514_bib32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jmsacl.2022.11.001","article-title":"LC\u2013MS\/MS method for simultaneous quantification of ten antibiotics in human plasma for routine therapeutic drug monitoring","volume":"26","author":"Radovanovic","year":"2022","journal-title":"J. Mass Spectrom. Adv. Clin. Lab"},{"key":"10.1016\/j.jpba.2026.117514_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.122160","article-title":"Validation and clinical application of a multiplex high performance liquid chromatography \u2013 tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections","volume":"1157","author":"Decosterd","year":"2020","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2026.117514_bib34","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40262-022-01113-6","article-title":"An integral pharmacokinetic analysis of piperacillin and tazobactam in plasma and urine in critically Ill patients","volume":"61","author":"Wallenburg","year":"2022","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.jpba.2026.117514_bib35","unstructured":"European Medicines Agency (EMA). ICH guideline M10 on bioanalytical method validation and study sample analysis (Step 5) (EMA\/CHMP\/ICH\/172948\/2019). 24 May 2022."},{"key":"10.1016\/j.jpba.2026.117514_bib36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.chroma.2006.03.078","article-title":"Secondary isotope effects in liquid chromatography behaviour of 2H and 3H labelled solutes and solvents","volume":"1116","author":"Valleix","year":"2006","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2026.117514_bib37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0378-5173(82)90179-X","article-title":"Stability kinetics of piperacillin in aqueous solutions","volume":"11","author":"Tsukinaka","year":"1982","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2026.117514_bib38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1752-153X-7-98","article-title":"Solid-state stability study of meropenem \u2013 solutions based on spectrophotometric analysis","volume":"7","author":"Cielecka-Piontek","year":"2013","journal-title":"Chem. Cent. J."},{"key":"10.1016\/j.jpba.2026.117514_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.tet.2024.134230","article-title":"A decade update on synthesis of bicyclic \u03b2-lactams and their transformation into synthetically\/biologically relevant carbocyclic and heterocyclic moieties","volume":"167","author":"Reshma","year":"2024","journal-title":"Tetrahedron"},{"key":"10.1016\/j.jpba.2026.117514_bib40","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ijantimicag.2016.06.013","article-title":"Variability of piperacillin concentrations in relation to tazobactam concentrations in critically ill patients","volume":"48","author":"Zander","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jpba.2026.117514_bib41","doi-asserted-by":"crossref","DOI":"10.1186\/cc13874","article-title":"Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study","volume":"18","author":"Blot","year":"2014","journal-title":"Crit. Care"},{"key":"10.1016\/j.jpba.2026.117514_bib42","doi-asserted-by":"crossref","DOI":"10.1186\/cc13984","article-title":"Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study","volume":"18","author":"Zoller","year":"2014","journal-title":"Crit. Care"},{"key":"10.1016\/j.jpba.2026.117514_bib43","article-title":"Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in human plasma using a sensitive and robust liquid chromatography-tandem mass spectrometry method, part 2: stability evaluation","volume":"62","author":"D\u2019Cunha","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2026.117514_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.119690","article-title":"A high performance liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of 10 drug compounds commonly used for antimicrobial therapy in plasma and serum of critically ill patients: method optimization, validation, cross-val","volume":"559","author":"Neef","year":"2024","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jpba.2026.117514_bib45","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1007\/BF01745246","article-title":"Pharmacokinetic characteristics of piperacillin\/tazobactam","volume":"20","author":"S\u00f6rgel","year":"1994","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jpba.2026.117514_bib46","first-page":"87","article-title":"Pharmacokinetic variability of beta-lactams in critically ill patients: a narrative review","volume":"39","author":"Boidin","year":"2020","journal-title":"Anaesth. Crit. Care Pain. Med."},{"key":"10.1016\/j.jpba.2026.117514_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcrc.2024.154828","article-title":"Determinants of beta-lactam PK\/PD target attainment in critically ill patients: a single center retrospective study","volume":"83","author":"Gand\u00e9ga","year":"2024","journal-title":"J. Crit. Care"},{"key":"10.1016\/j.jpba.2026.117514_bib48","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00134-006-0470-5","article-title":"Pharmacokinetic\/pharmacodynamic analysis of vancomycin in ICU patients","volume":"33","author":"del Mar Fern\u00e1ndez de Gatta Garcia","year":"2007","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jpba.2026.117514_bib49","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40262-016-0463-7","article-title":"Clinical determinants of target non-attainment of linezolid in plasma and interstitial space fluid: a pooled population pharmacokinetic analysis with focus on critically Ill Patients","volume":"56","author":"Minichmayr","year":"2017","journal-title":"Clin. Pharm."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526001822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526001822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:02:32Z","timestamp":1778752952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708526001822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":49,"alternative-id":["S0731708526001822"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117514","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of an UHPLC-MS\/MS method for simultaneous quantification of Tazobactam, Meropenem, Vancomycin, Linezolid and Piperacillin in human plasma: Application in critically ill patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117514","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117514"}}